Consumer-facing investments increased 400 basis points for the full year, contributing to margin pressure but fueling growth.
Diluted EPS decreased 42% year-over-year, with Q4 EPS at $0.09 versus $0.64 last year.
Fiscal 2025 full year organic sales declined 8%, with nearly two-thirds of the decline from travel retail, which fell 28%.
Fourth quarter organic net sales declined 13%, with all categories down except fragrance, and travel retail as a primary driver.
Generated $1.3 billion net cash flow from operations in fiscal 2025, down from $2.4 billion prior year, impacted by lower earnings and restructuring payments.
Gross margin expanded 230 basis points to 74%, exceeding May outlook by 50 basis points despite volume deleverage.
Operating margin contracted 220 basis points to 8%, driven by sales declines and increased consumer-facing investments.
Recorded $425 million impairment charges in Q4 related to Dr.Jart+ and Too Faced due to underperformance in key markets.
Adjusted EPS for fiscal 2025 was $0.50, at the upper end of guidance, with 4% growth despite lower operating income.
Adjusted gross margin expanded by 50 basis points to 64.9% in fiscal 2025, driven by supply chain savings and pricing carryover benefits.
Fiscal year 2025 adjusted EBITDA was $1.08 billion, slightly down but with a margin expansion of 60 basis points to 18.4%.
Free cash flow was $278 million, slightly below the $300 million target due to lower cash profits and higher customer overdues.
Leverage ratio improved from 6.8x in fiscal 2021 to 3.5x in fiscal 2025, despite a 0.2 turn increase in Q4 due to U.S. dollar depreciation adding $200 million to debt.
Net revenues declined 2% like-for-like in fiscal 2025 and 9% in Q4, reflecting retailer destocking and lapping blockbuster launches from fiscal 2024.
Q4 adjusted EBITDA declined 23% due to operating deleverage from lower sales and gross margin contraction.